Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.41 |
| ▸ | GFER | P55789 | 2/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | EIF2AK4 | Q9P2K8 | 4/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | CCNK | O75909 | 1/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2038024 | 0.88 | EIF2AK4 (0.42) | FLT3ADORA2AIGF1REIF2AK4 | |
| SCHEMBL2038025 | 0.88 | EIF2AK4 (0.42) | FLT3ADORA2AIGF1REIF2AK4 | |
| SCHEMBL2039977 | 0.88 | JAK2 (0.47) | FLT3ADORA2AGFERIGF1REIF2AK4 | |
| SCHEMBL2034765 | 0.88 | ADORA2A (0.41) | FLT3ADORA2AGFEREIF2AK4JAK2 | |
| SCHEMBL2033048 | 0.88 | EGLN2 (0.40) | FLT3ADORA2AGFEREIF2AK4JAK2 | |
| SCHEMBL2036807 | 0.87 | EIF2AK4 (0.47) | FLT3ADORA2AEIF2AK4JAK2JAK1 | |
| SCHEMBL2040086 | 0.86 | ADORA2A (0.43) | FLT3ADORA2AGFERIGF1REIF2AK4 | |
| SCHEMBL2033554 | 0.86 | IRAK4 (0.41) | FLT3ADORA2AEIF2AK4JAK2JAK1 | |
| SCHEMBL2033334 | 0.85 | FLT3 (0.41) | FLT3ADORA2AIGF1REIF2AK4JAK2 | |
| SCHEMBL16824789 | 0.85 | FLT3 (0.41) | FLT3ADORA2AIGF1REIF2AK4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | FLT3 21/4885ADORA2A 3489/4885GFER 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.